Generics in Asia-Pacific
Published: August 2013 · Publisher: MarketLine
Generics in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Generics in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Asia-Pacific generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The Asia-Pacific generics market had total revenues of $64.9bn in 2012, representing a compound annual growth rate (CAGR) of 16.3% between 2008 and 2012.
*Market consumption volume increased with a CAGR of 1.5% between 2008-2012, to reach a total of 87.4% of total pharma volume in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 12.6% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $117.4bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Asia-Pacific
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Asia-Pacific
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Asia-Pacific economy
Key Questions Answered
What was the size of the Asia-Pacific generics market by value in 2012?
What will be the size of the Asia-Pacific generics market in 2017?
What factors are affecting the strength of competition in the Asia-Pacific generics market?
How has the market performed over the last five years?
What are the main segments that make up Asia-Pacific's generics market?
Generics in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Asia-Pacific generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The Asia-Pacific generics market had total revenues of $64.9bn in 2012, representing a compound annual growth rate (CAGR) of 16.3% between 2008 and 2012.
*Market consumption volume increased with a CAGR of 1.5% between 2008-2012, to reach a total of 87.4% of total pharma volume in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 12.6% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $117.4bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Asia-Pacific
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Asia-Pacific
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Asia-Pacific economy
Key Questions Answered
What was the size of the Asia-Pacific generics market by value in 2012?
What will be the size of the Asia-Pacific generics market in 2017?
What factors are affecting the strength of competition in the Asia-Pacific generics market?
How has the market performed over the last five years?
What are the main segments that make up Asia-Pacific's generics market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
China Grand Pharmaceutical and Healthcare Holdings Limited, Daiichi Sankyo Co., Ltd., Nichi-iko Pharmaceutical and Sawai Pharmaceutical Co., Ltd.
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
China Grand Pharmaceutical and Healthcare Holdings Limited 20
Daiichi Sankyo Co., Ltd. 23
Nichi-iko Pharmaceutical 26
Sawai Pharmaceutical Co., Ltd. 29
Appendix 32
Methodology 32
Industry associations 33
Related research 33
LIST OF TABLES
Table 1: Asia-Pacific generics market value: $ million, 2008–12 8
Table 2: Asia–Pacific generics market volume: % of total pharma volume, 2008–12 9
Table 3: Asia–Pacific generics market geography segmentation: $ million, 2012 10
Table 4: Asia-Pacific generics market value forecast: $ million, 2012–17 11
Table 5: Asia–Pacific generics market volume forecast: % of total pharma volume, 2012–17 12
Table 6: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts 20
Table 7: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($) 21
Table 8: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY) 21
Table 9: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios 21
Table 10: Daiichi Sankyo Co., Ltd.: key facts 23
Table 11: Daiichi Sankyo Co., Ltd.: key financials ($) 23
Table 12: Daiichi Sankyo Co., Ltd.: key financials (¥) 24
Table 13: Daiichi Sankyo Co., Ltd.: key financial ratios 24
Table 14: Nichi-iko Pharmaceutical: key facts 26
Table 15: Nichi-iko Pharmaceutical: key financials ($) 27
Table 16: Nichi-iko Pharmaceutical: key financials (¥) 27
Table 17: Nichi-iko Pharmaceutical: key financial ratios 27
Table 18: Sawai Pharmaceutical Co., Ltd.: key facts 29
Table 19: Sawai Pharmaceutical Co., Ltd.: key financials ($) 29
Table 20: Sawai Pharmaceutical Co., Ltd.: key financials (¥) 30
Table 21: Sawai Pharmaceutical Co., Ltd.: key financial ratios 30
LIST OF FIGURES
Figure 1: Asia-Pacific generics market value: $ million, 2008–12 8
Figure 2: Asia–Pacific generics market volume: % of total pharma volume, 2008–12 9
Figure 3: Asia–Pacific generics market geography segmentation: % share, by value, 2012 10
Figure 4: Asia-Pacific generics market value forecast: $ million, 2012–17 11
Figure 5: Asia–Pacific generics market volume forecast: % of total pharma volume, 2012–17 12
Figure 6: Forces driving competition in the generics market in Asia-Pacific, 2012 13
Figure 7: Drivers of buyer power in the generics market in Asia-Pacific, 2012 15
Figure 8: Drivers of supplier power in the generics market in Asia-Pacific, 2012 16
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2012 17
Figure 10: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2012 18
Figure 11: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2012 19
Figure 12: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability 22
Figure 13: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities 22
Figure 14: Daiichi Sankyo Co., Ltd.: revenues & profitability 24
Figure 15: Daiichi Sankyo Co., Ltd.: assets & liabilities 25
Figure 16: Nichi-iko Pharmaceutical: revenues & profitability 28
Figure 17: Nichi-iko Pharmaceutical: assets & liabilities 28
Figure 18: Sawai Pharmaceutical Co., Ltd.: revenues & profitability 30
Figure 19: Sawai Pharmaceutical Co., Ltd.: assets & liabilities 31
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
China Grand Pharmaceutical and Healthcare Holdings Limited 20
Daiichi Sankyo Co., Ltd. 23
Nichi-iko Pharmaceutical 26
Sawai Pharmaceutical Co., Ltd. 29
Appendix 32
Methodology 32
Industry associations 33
Related research 33
LIST OF TABLES
Table 1: Asia-Pacific generics market value: $ million, 2008–12 8
Table 2: Asia–Pacific generics market volume: % of total pharma volume, 2008–12 9
Table 3: Asia–Pacific generics market geography segmentation: $ million, 2012 10
Table 4: Asia-Pacific generics market value forecast: $ million, 2012–17 11
Table 5: Asia–Pacific generics market volume forecast: % of total pharma volume, 2012–17 12
Table 6: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts 20
Table 7: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($) 21
Table 8: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY) 21
Table 9: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios 21
Table 10: Daiichi Sankyo Co., Ltd.: key facts 23
Table 11: Daiichi Sankyo Co., Ltd.: key financials ($) 23
Table 12: Daiichi Sankyo Co., Ltd.: key financials (¥) 24
Table 13: Daiichi Sankyo Co., Ltd.: key financial ratios 24
Table 14: Nichi-iko Pharmaceutical: key facts 26
Table 15: Nichi-iko Pharmaceutical: key financials ($) 27
Table 16: Nichi-iko Pharmaceutical: key financials (¥) 27
Table 17: Nichi-iko Pharmaceutical: key financial ratios 27
Table 18: Sawai Pharmaceutical Co., Ltd.: key facts 29
Table 19: Sawai Pharmaceutical Co., Ltd.: key financials ($) 29
Table 20: Sawai Pharmaceutical Co., Ltd.: key financials (¥) 30
Table 21: Sawai Pharmaceutical Co., Ltd.: key financial ratios 30
LIST OF FIGURES
Figure 1: Asia-Pacific generics market value: $ million, 2008–12 8
Figure 2: Asia–Pacific generics market volume: % of total pharma volume, 2008–12 9
Figure 3: Asia–Pacific generics market geography segmentation: % share, by value, 2012 10
Figure 4: Asia-Pacific generics market value forecast: $ million, 2012–17 11
Figure 5: Asia–Pacific generics market volume forecast: % of total pharma volume, 2012–17 12
Figure 6: Forces driving competition in the generics market in Asia-Pacific, 2012 13
Figure 7: Drivers of buyer power in the generics market in Asia-Pacific, 2012 15
Figure 8: Drivers of supplier power in the generics market in Asia-Pacific, 2012 16
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2012 17
Figure 10: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2012 18
Figure 11: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2012 19
Figure 12: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability 22
Figure 13: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities 22
Figure 14: Daiichi Sankyo Co., Ltd.: revenues & profitability 24
Figure 15: Daiichi Sankyo Co., Ltd.: assets & liabilities 25
Figure 16: Nichi-iko Pharmaceutical: revenues & profitability 28
Figure 17: Nichi-iko Pharmaceutical: assets & liabilities 28
Figure 18: Sawai Pharmaceutical Co., Ltd.: revenues & profitability 30
Figure 19: Sawai Pharmaceutical Co., Ltd.: assets & liabilities 31
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.